Two drugs taken together can sometimes lead to outcomes that largely deviate from the effect of the separated compounds – a fact well known from warnings on patient information leaflets. However, while doctors strongly advice against unsupervised mixing of drugs, the synergy of two combined pharmaceuticals assessed in an experimental setting can reveal completely new therapeutic options. Nevertheless, finding a novel combination of drugs for a given disease within the more than 30,000 drug products approved by the regulatory agencies was hitherto a big challenge for scientists.
To facilitate systematic screening for synergistic interactions of drugs, CeMM PI Stefan Kubicek and his colleagues established a collection of 308 compounds (CeMM Library of Unique Drugs, CLOUD) that effectively represent the diversity of structures and molecular targets of all FDA-approved chemical entities. Moreover, the scientists proved the potential of the CLOUD with CeMM´s highly automated chemical screening platform by identifying a novel synergistic effect of two drugs (flutamide and phenprocoumon (PPC)) on prostate cancer cells. The results of Kubicek´s team with Marco Licciardello as first author were published in Nature Chemical Biology(DOI:10.1038/nchembio.2382)
For the establishment of the CLOUD, a clever series of condensation steps was necessary: the CeMM scientists first determined and extracted 2171 unique active pharmaceutical ingredients from the database, discarding all products with identical compounds. Next, they removed large macromolecules like antibodies as well as salt fragments, and discarded all molecules that exert their biological effects through mechanisms other than protein-ligand interactions, are not used to treat diseases or are found only in topical products.
With the remaining 954 systemically active small molecules (STEAM collection), the work had just begun: in order to create a comprehensive collection of compounds that fits on a standard 384-well screening plate, the researchers appended biological activities to all drugs with known molecular targets and grouped them into 176 classes of similar structure and activity. With a sophisticated clustering algorithm, 239 representative drugs were selected from those classes. Combined with 34 drugs with unknown target and 35 active forms of prodrugs (that otherwise need to be metabolized to become active), 308 compounds were selected in total for the CLOUD – the world´s first library representing all FDA-approved chemical entities including the active form of prodrugs.
To put the combinatorial screen with the CLOUD to the test, Kubicek’s group investigated the effect of pairwise combinations of CLOUD compounds on the viability on KBM7 leukemia cells, a cell line well suited for drug experiments. Using a dose chosen for each compound individually based on the clinically relevant maximum plasma concentration, the scientists found a strong synergistic interaction between flutamide, a drug approved for the treatment of prostate cancer, and phenprocoumon (PPC), an anti-thrombosis compound. In combination, flutamide and PPC efficiently killed the cancer cells.
After identifying the androgen receptor (AR) as molecular target of the synergistic interaction, the scientists tried the drug combination on prostate cancer cells known to be hard to treat – and hit the bulls eye. “The combination induced massive cell death in prostate cancer cells. We then went back to the entire approved drug list, and indeed, we could show that all drugs from the clusters that flutamide and phenprocoumon represent synergize. Thereby we validated the reductionist concept underlying the CLOUD library,” Stefan Kubicek explains.
With their experiments, Kubicek´s team in collaboration with scientists from the Medical University of Vienna, the Uppsala University, Enamine Kiev and the Max Planck Institute for Informatics in Saarbrücken proved that the CLOUD is the ideal set of compounds to develop screening assays and discover new applications for approved active ingredients. At CeMM, a number of key discoveries on new applications for approved drugs have already been made with the CLOUD. Furthermore, as shown in the current issue of Nature Chemical Biology, the CLOUD is ideal for finding new drug combinations. “In view of these successes, I would predict that this set of compounds will become world standard for all screening campaigns”, Stefan Kubicek emphasizes.
The Latest on: Synergistic interactions of drugs
Gene–Drug Interaction Map Developed to Aid Personalized Chemotherapy
on April 18, 2018 at 7:05 am
“This quantitative map is predictive of interactions maintained in other cell lines, identifies DNA-repair factors, predicts cancer cell line responses to therapy, and prioritizes synergistic drug combinations.…In contrast to most standard genetic ... […]
Novel proteomics strategies aid cancer research
on April 17, 2018 at 12:51 pm
Combining drugs is a preferred way to treat cancer patients, because drug combinations can offer additive or synergistic effects and delay ... of proteins affect biological responses, and how the interaction of proteins with their cellular partners ... […]
Eight presentations on SPR741 at ECCMID, collectively supporting its activity, safety and tolerability
on April 16, 2018 at 5:26 am
A Phase 1b drug-drug interaction trial of SPR741 is ongoing to assess the ... The following posters characterize the activity and synergistic effects of SPR741 in combination with a partner antibiotic: Bactericidal activity of ceftazidime in combination ... […]
ContraVir Pharmaceuticals Announces New Data Presented at the 2018 International Liver Congress™
on April 12, 2018 at 10:14 am
ranged from moderately to strongly synergistic. None of the combinations tested showed evidence of antagonism. Curative regimens for treatment of HBV will likely require combination of drugs that work via different mechanisms addressing viremia (HBV DNA ... […]
CytoDyn And HIV Therapy: CCR5 Antagonist Is An Old Drug Made New
on March 25, 2018 at 5:45 am
On the other hand, it has been speculated that since small molecule antagonists like MVC may have fewer interactions ... synergistic effective antiviral responses in R5 HIV patients. Moreover, PRO 140 may also have therapeutic efficacy in individuals (drug ... […]
via Google News and Bing News